User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

The role of solithromycin in the management of bacterial community-acquired pneumonia.

Primary tabs

Van Bambeke, Françoise [UCL] Tulkens, Paul M. [UCL]

The fluoroketolide solithromycin is 2-fold more potent in vitro than telithromycin against pneumococci (including macrolide-resistant strains) and Haemophilus influenzae and very active on pathogens causing atypical pneumonia. In contrast, it is a 30-fold less potent inhibitor of nicotinic receptors incriminated in telithromycin toxicity. In Phase II/III trials, oral solithromycin once-daily (800 mg on day 1; 400 mg on days 2-5) proved effective and safe when compared to respiratory fluoroquinolones for the treatment of community-acquired bacterial pneumonia (CABP). A Phase III intravenous trial vs. moxifloxacin has been recently completed for the same indication. Solithromycin may restore interest in ketolides as a first-line therapy for CAPB. Solithromycin safety should nevertheless be confirmed in larger populations allowing for detection of rare adverse events.

Document type Article de périodique (Journal article) – Synthèse de littérature
Publication date 2016
Language Anglais
Journal information "Expert Review of Anti-infective Therapy" - Vol. 14, no.3, p. 311-324 (2016)
Peer reviewed yes
Publisher Expert Reviews Ltd. (London)
issn 1478-7210
e-issn 1744-8336
Publication status Publié
Affiliation UCL - SSS/LDRI - Louvain Drug Research Institute
Links
  1. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013, 10.1016/s0140-6736(14)61682-2
  2. Drijkoningen J.J.C., Rohde G.G.U., Pneumococcal infection in adults: burden of disease, 10.1111/1469-0691.12461
  3. Wallihan Rebecca, Ramilo Octavio, Community-acquired pneumonia in children: Current challenges and future directions, 10.1016/j.jinf.2014.07.021
  4. Jackson Michael L., Neuzil Kathleen M., Thompson William W., Shay David K., Yu Onchee, Hanson Christi A., Jackson Lisa A., The Burden of Community‐Acquired Pneumonia in Seniors: Results of a Population‐Based Study, 10.1086/425615
  5. Prina Elena, Ranzani Otavio T, Torres Antoni, Community-acquired pneumonia, 10.1016/s0140-6736(15)60733-4
  6. Welte T, Torres A, Nathwani D, Clinical and economic burden of community-acquired pneumonia among adults in Europe, 10.1136/thx.2009.129502
  7. Aliberti Stefano, Kaye Keith S., The Changing Microbiologic Epidemiology of Community-Acquired Pneumonia, 10.3810/pgm.2013.11.2710
  8. Restrepo Marcos I., Faverio Paola, Anzueto Antonio, Long-term prognosis in community-acquired pneumonia : , 10.1097/qco.0b013e32835ebc6d
  9. Torres A., Blasi F., Peetermans W. E., Viegi G., Welte T., The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review, 10.1007/s10096-014-2067-1
  10. Rozenbaum M. H., Pechlivanoglou P., Werf T. S., Lo-Ten-Foe J. R., Postma M. J., Hak E., The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis, 10.1007/s10096-012-1778-4
  11. Klapdor Benjamin, Ewig Santiago, Pletz Mathias W., Rohde Gernot, Schütte Hartwig, Schaberg Tom, Welte Tobias, Community-acquired pneumonia in younger patients is an entity on its own, 10.1183/09031936.00110911
  12. Ewig Santiago, Klapdor Benjamin, Pletz Mathias W, Rohde Gernot, Schütte Hartwig, Schaberg Tom, Bauer Torsten T, Welte Tobias, , Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study, 10.1136/thoraxjnl-2011-200630
  13. Peto Leon, Nadjm Behzad, Horby Peter, Ngan Ta Thi Dieu, van Doorn Rogier, Kinh Nguyen Van, Wertheim Heiman F. L., The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review, 10.1093/trstmh/tru058
  14. Niederman Michael S., Community-Acquired Pneumonia, 10.7326/aitc201510060
  15. Lee Young R, Houngue Coovi, Hall Ronald G, Treatment of community-acquired pneumonia, 10.1586/14787210.2015.1060125
  16. Mandell Lionel A., Wunderink Richard G., Anzueto Antonio, Bartlett John G., Campbell G. Douglas, Dean Nathan C., Dowell Scott F., File Thomas M., Musher Daniel M., Niederman Michael S., Torres Antonio, Whitney Cynthia G., Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults, 10.1086/511159
  17. Woodhead M, Clin Microbiol Infect, 17, E1E59 (2011)
  18. Lim W S, Smith D L, Wise M P, Welham S A, British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together: Table 1, 10.1136/bmjresp-2015-000091
  19. Mpenge Mbiye, MacGowan Alasdair, Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia, 10.2147/tcrm.s75412
  20. Liapikou A, Drug Des Devel Ther, 9, 4565 (2015)
  21. Van Bambeke Françoise, Macrolides and Ketolides, Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics (2014) ISBN:9780387756127 p.257-278, 10.1007/978-0-387-75613-4_11
  22. Kim S. H., Song J.-H., Chung D. R., Thamlikitkul V., Yang Y., Wang H., Lu M., So T. M.-k., Hsueh P.-R., Yasin R. M., Carlos C. C., Pham H. V., Lalitha M. K., Shimono N., Perera J., Shibl A. M., Baek J. Y., Kang C.-I., Ko K. S., Peck K. R., , Changing Trends in Antimicrobial Resistance and Serotypes of Streptococcus pneumoniae Isolates in Asian Countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study, 10.1128/aac.05658-11
  23. Bielicki Julia Anna, Lundin Rebecca, Sharland Mike, Antibiotic Resistance Prevalence in Routine Bloodstream Isolates from Children’s Hospitals Varies Substantially from Adult Surveillance Data in Europe : , 10.1097/inf.0000000000000652
  24. Pfaller Michael A., Farrell David J., Sader Helio S., Jones Ronald N., AWARE Ceftaroline Surveillance Program (2008–2010): Trends in Resistance Patterns Among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States, 10.1093/cid/cis561
  25. Wierzbowski A. K., Karlowsky J. A., Adam H. J., Nichol K. A., Hoban D. J., Zhanel G. G., , Evolution and molecular characterization of macrolide-resistant Streptococcus pneumoniae in Canada between 1998 and 2008, 10.1093/jac/dkt332
  26. Diaz Maureen H., Benitez Alvaro J., Winchell Jonas M., Investigations of Mycoplasma pneumoniae Infections in the United States: Trends in Molecular Typing and Macrolide Resistance from 2006 to 2013, 10.1128/jcm.02597-14
  27. Liu Y., Ye X., Zhang H., Xu X., Li W., Zhu D., Wang M., Antimicrobial Susceptibility of Mycoplasma pneumoniae Isolates and Molecular Analysis of Macrolide-Resistant Strains from Shanghai, China, 10.1128/aac.01684-08
  28. Van Bambeke Françoise, Reinert René R, Appelbaum Peter C, Tulkens Paul M, Peetermans Willy E, Multidrug-Resistant Streptococcus pneumoniae Infections : Current and Future Therapeutic Options, 10.2165/00003495-200767160-00005
  29. Pai Manjunath P., Momary Kathryn M., Rodvold Keith A., Antibiotic Drug Interactions, 10.1016/j.mcna.2006.06.008
  30. Abo-Salem Elsayed, Fowler John C., Attari Mehran, Cox Craig D., Perez-Verdia Alejandro, Panikkath Ragesh, Nugent Kenneth, Antibiotic-induced Cardiac Arrhythmias, 10.1111/1755-5922.12054
  31. Andrade R. J., Tulkens P. M., Hepatic safety of antibiotics used in primary care, 10.1093/jac/dkr159
  32. Broad John, Sanger Gareth J, The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin : Azithromycin is a motilin agonist in human stomach, 10.1111/bph.12077
  33. McFarlane Alexandra, Sligl Wendy, The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia, 10.1007/s11908-015-0507-4
  34. Skalsky K., Yahav D., Lador A., Eliakim-Raz N., Leibovici L., Paul M., Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials, 10.1111/j.1469-0691.2012.03838.x
  35. Cilloniz Catia, Albert Richard K., Liapikou Adamanthia, Gabarrus Albert, Rangel Ernesto, Bello Salvador, Marco Francesc, Mensa Josep, Torres Antoni, The Effect of Macrolide Resistance on the Presentation and Outcome of Patients Hospitalized forStreptococcus pneumoniaePneumonia, 10.1164/rccm.201502-0212oc
  36. Kovaleva A., Remmelts H. H. F., Rijkers G. T., Hoepelman A. I. M., Biesma D. H., Oosterheert J. J., Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review, 10.1093/jac/dkr520
  37. Emmet O’Brien M., Restrepo Marcos I., Martin-Loeches Ignacio, Update on the combination effect of macrolide antibiotics in community-acquired pneumonia, 10.1016/j.resinv.2015.05.003
  38. Garin Nicolas, Genné Daniel, Carballo Sebastian, Chuard Christian, Eich Gerhardt, Hugli Olivier, Lamy Olivier, Nendaz Mathieu, Petignat Pierre-Auguste, Perneger Thomas, Rutschmann Olivier, Seravalli Laurent, Harbarth Stephan, Perrier Arnaud, β-Lactam Monotherapy vs β-Lactam–Macrolide Combination Treatment in Moderately Severe Community-Acquired Pneumonia : A Randomized Noninferiority Trial, 10.1001/jamainternmed.2014.4887
  39. Ambroggio Lilliam, Test Matthew, Metlay Joshua P., Graf Thomas R., Blosky Mary Ann, Macaluso Maurizio, Shah Samir S., Beta-lactam versus beta- lactam/macrolide therapy in pediatric outpatient pneumonia : Antibiotic Therapy for Outpatient CAP, 10.1002/ppul.23312
  40. Van Bambeke Françoise, Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones, 10.3109/07853890.2014.935470
  41. Van Bambeke Françoise, Harms Joerg M, Van Laethem Yves, Tulkens Paul M, Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections, 10.1517/14656566.9.2.267
  42. Bertrand D., Bertrand S., Neveu E., Fernandes P., Molecular Characterization of Off-Target Activities of Telithromycin: a Potential Role for Nicotinic Acetylcholine Receptors, 10.1128/aac.00840-10
  43. Llano-Sotelo B., Dunkle J., Klepacki D., Zhang W., Fernandes P., Cate J. H. D., Mankin A. S., Binding and Action of CEM-101, a New Fluoroketolide Antibiotic That Inhibits Protein Synthesis, 10.1128/aac.00860-10
  44. Rodgers W., Frazier A. D., Champney W. S., Solithromycin Inhibition of Protein Synthesis and Ribosome Biogenesis in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae, 10.1128/aac.02316-12
  45. Gupta Pulkit, Kannan Krishna, Mankin Alexander S., Vázquez-Laslop Nora, Regulation of Gene Expression by Macrolide-Induced Ribosomal Frameshifting, 10.1016/j.molcel.2013.10.013
  46. Farrell David J., Sader Helio S., Castanheira Mariana, Biedenbach Douglas J., Rhomberg Paul R., Jones Ronald N., Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates, 10.1016/j.ijantimicag.2010.01.026
  47. Farrell D. J., Mendes R. E., Jones R. N., Antimicrobial Activity of Solithromycin against Serotyped Macrolide-Resistant Streptococcus pneumoniae Isolates Collected from U.S. Medical Centers in 2012, 10.1128/aac.04568-14
  48. Putnam Shannon D., Sader Helio S., Farrell David J., Biedenbach Douglas J., Castanheira Mariana, Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci, 10.1016/j.ijantimicag.2010.08.021
  49. Roblin P. M., Kohlhoff S. A., Parker C., Hammerschlag M. R., In Vitro Activity of CEM-101, a New Fluoroketolide Antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae, 10.1128/aac.01343-09
  50. Mallegol J., Fernandes P., Melano R. G., Guyard C., Antimicrobial Activity of Solithromycin against Clinical Isolates of Legionella pneumophila Serogroup 1, 10.1128/aac.01639-13
  51. Vandevelde N. M., Tulkens P. M., Van Bambeke F., Antibiotic Activity against Naive and Induced Streptococcus pneumoniae Biofilms in an In Vitro Pharmacodynamic Model, 10.1128/aac.01858-13
  52. Lemaire S., Van Bambeke F., Tulkens P. M., Cellular Accumulation and Pharmacodynamic Evaluation of the Intracellular Activity of CEM-101, a Novel Fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in Human THP-1 Macrophages, 10.1128/aac.00203-09
  53. Still J. G., Schranz J., Degenhardt T. P., Scott D., Fernandes P., Gutierrez M. J., Clark K., Pharmacokinetics of Solithromycin (CEM-101) after Single or Multiple Oral Doses and Effects of Food on Single-Dose Bioavailability in Healthy Adult Subjects, 10.1128/aac.01429-10
  54. Rodvold K. A., Gotfried M. H., Still J. G., Clark K., Fernandes P., Comparison of Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Solithromycin (CEM-101) in Healthy Adult Subjects, 10.1128/aac.00766-12
  55. Jamieson Brian D., Ciric Sabrina, Fernandes Prabhavathi, Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment, 10.1128/aac.04652-14
  56. Kobayashi Y., Wada H., Rossios C., Takagi D., Higaki M., Mikura S., Goto H., Barnes P. J., Ito K., A Novel Macrolide Solithromycin Exerts Superior Anti-inflammatory Effect via NF- B Inhibition, 10.1124/jpet.112.200733
  57. Kobayashi Y, Wada H, Rossios C, Takagi D, Charron C, Barnes P J, Ito K, A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition : Solithromycin reverses corticosteroid insensitivity, 10.1111/bph.12187
  58. Oldach D., Clark K., Schranz J., Das A., Craft J. C., Scott D., Jamieson B. D., Fernandes P., Randomized, Double-Blind, Multicenter Phase 2 Study Comparing the Efficacy and Safety of Oral Solithromycin (CEM-101) to Those of Oral Levofloxacin in the Treatment of Patients with Community-Acquired Bacterial Pneumonia, 10.1128/aac.00197-13
  59. Walker Christa L Fischer, Rudan Igor, Liu Li, Nair Harish, Theodoratou Evropi, Bhutta Zulfiqar A, O'Brien Katherine L, Campbell Harry, Black Robert E, Global burden of childhood pneumonia and diarrhoea, 10.1016/s0140-6736(13)60222-6
  60. Murray Christopher J L, Vos Theo, Lozano Rafael, Naghavi Mohsen, Flaxman Abraham D, Michaud Catherine, Ezzati Majid, Shibuya Kenji, Salomon Joshua A, Abdalla Safa, Aboyans Victor, Abraham Jerry, Ackerman Ilana, Aggarwal Rakesh, Ahn Stephanie Y, Ali Mohammed K, AlMazroa Mohammad A, Alvarado Miriam, Anderson H Ross, Anderson Laurie M, Andrews Kathryn G, Atkinson Charles, Baddour Larry M, Bahalim Adil N, Barker-Collo Suzanne, Barrero Lope H, Bartels David H, Basáñez Maria-Gloria, Baxter Amanda, Bell Michelle L, Benjamin Emelia J, Bennett Derrick, Bernabé Eduardo, Bhalla Kavi, Bhandari Bishal, Bikbov Boris, Abdulhak Aref Bin, Birbeck Gretchen, Black James A, Blencowe Hannah, Blore Jed D, Blyth Fiona, Bolliger Ian, Bonaventure Audrey, Boufous Soufiane, Bourne Rupert, Boussinesq Michel, Braithwaite Tasanee, Brayne Carol, Bridgett Lisa, Brooker Simon, Brooks Peter, Brugha Traolach S, Bryan-Hancock Claire, Bucello Chiara, Buchbinder Rachelle, Buckle Geoffrey, Budke Christine M, Burch Michael, Burney Peter, Burstein Roy, Calabria Bianca, Campbell Benjamin, Canter Charles E, Carabin Hélène, Carapetis Jonathan, Carmona Loreto, Cella Claudia, Charlson Fiona, Chen Honglei, Cheng Andrew Tai-Ann, Chou David, Chugh Sumeet S, Coffeng Luc E, Colan Steven D, Colquhoun Samantha, Colson K Ellicott, Condon John, Connor Myles D, Cooper Leslie T, Corriere Matthew, Cortinovis Monica, de Vaccaro Karen Courville, Couser William, Cowie Benjamin C, Criqui Michael H, Cross Marita, Dabhadkar Kaustubh C, Dahiya Manu, Dahodwala Nabila, Damsere-Derry James, Danaei Goodarz, Davis Adrian, Leo Diego De, Degenhardt Louisa, Dellavalle Robert, Delossantos Allyne, Denenberg Julie, Derrett Sarah, Des Jarlais Don C, Dharmaratne Samath D, Dherani Mukesh, Diaz-Torne Cesar, Dolk Helen, Dorsey E Ray, Driscoll Tim, Duber Herbert, Ebel Beth, Edmond Karen, Elbaz Alexis, Ali Suad Eltahir, Erskine Holly, Erwin Patricia J, Espindola Patricia, Ewoigbokhan Stalin E, Farzadfar Farshad, Feigin Valery, Felson David T, Ferrari Alize, Ferri Cleusa P, Fèvre Eric M, Finucane Mariel M, Flaxman Seth, Flood Louise, Foreman Kyle, Forouzanfar Mohammad H, Fowkes Francis Gerry R, Fransen Marlene, Freeman Michael K, Gabbe Belinda J, Gabriel Sherine E, Gakidou Emmanuela, Ganatra Hammad A, Garcia Bianca, Gaspari Flavio, Gillum Richard F, Gmel Gerhard, Gonzalez-Medina Diego, Gosselin Richard, Grainger Rebecca, Grant Bridget, Groeger Justina, Guillemin Francis, Gunnell David, Gupta Ramyani, Haagsma Juanita, Hagan Holly, Halasa Yara A, Hall Wayne, Haring Diana, Haro Josep Maria, Harrison James E, Havmoeller Rasmus, Hay Roderick J, Higashi Hideki, Hill Catherine, Hoen Bruno, Hoffman Howard, Hotez Peter J, Hoy Damian, Huang John J, Ibeanusi Sydney E, Jacobsen Kathryn H, James Spencer L, Jarvis Deborah, Jasrasaria Rashmi, Jayaraman Sudha, Johns Nicole, Jonas Jost B, Karthikeyan Ganesan, Kassebaum Nicholas, Kawakami Norito, Keren Andre, Khoo Jon-Paul, King Charles H, Knowlton Lisa Marie, Kobusingye Olive, Koranteng Adofo, Krishnamurthi Rita, Laden Francine, Lalloo Ratilal, Laslett Laura L, Lathlean Tim, Leasher Janet L, Lee Yong Yi, Leigh James, Levinson Daphna, Lim Stephen S, Limb Elizabeth, Lin John Kent, Lipnick Michael, Lipshultz Steven E, Liu Wei, Loane Maria, Ohno Summer Lockett, Lyons Ronan, Mabweijano Jacqueline, MacIntyre Michael F, Malekzadeh Reza, Mallinger Leslie, Manivannan Sivabalan, Marcenes Wagner, March Lyn, Margolis David J, Marks Guy B, Marks Robin, Matsumori Akira, Matzopoulos Richard, Mayosi Bongani M, McAnulty John H, McDermott Mary M, McGill Neil, McGrath John, Medina-Mora Maria Elena, Meltzer Michele, Memish Ziad A, Mensah George A, Merriman Tony R, Meyer Ana-Claire, Miglioli Valeria, Miller Matthew, Miller Ted R, Mitchell Philip B, Mock Charles, Mocumbi Ana Olga, Moffitt Terrie E, Mokdad Ali A, Monasta Lorenzo, Montico Marcella, Moradi-Lakeh Maziar, Moran Andrew, Morawska Lidia, Mori Rintaro, Murdoch Michele E, Mwaniki Michael K, Naidoo Kovin, Nair M Nathan, Naldi Luigi, Narayan K M Venkat, Nelson Paul K, Nelson Robert G, Nevitt Michael C, Newton Charles R, Nolte Sandra, Norman Paul, Norman Rosana, O'Donnell Martin, O'Hanlon Simon, Olives Casey, Omer Saad B, Ortblad Katrina, Osborne Richard, Ozgediz Doruk, Page Andrew, Pahari Bishnu, Pandian Jeyaraj Durai, Rivero Andrea Panozo, Patten Scott B, Pearce Neil, Padilla Rogelio Perez, Perez-Ruiz Fernando, Perico Norberto, Pesudovs Konrad, Phillips David, Phillips Michael R, Pierce Kelsey, Pion Sébastien, Polanczyk Guilherme V, Polinder Suzanne, Pope C Arden, Popova Svetlana, Porrini Esteban, Pourmalek Farshad, Prince Martin, Pullan Rachel L, Ramaiah Kapa D, Ranganathan Dharani, Razavi Homie, Regan Mathilda, Rehm Jürgen T, Rein David B, Remuzzi Guiseppe, Richardson Kathryn, Rivara Frederick P, Roberts Thomas, Robinson Carolyn, De Leòn Felipe Rodriguez, Ronfani Luca, Room Robin, Rosenfeld Lisa C, Rushton Lesley, Sacco Ralph L, Saha Sukanta, Sampson Uchechukwu, Sanchez-Riera Lidia, Sanman Ella, Schwebel David C, Scott James Graham, Segui-Gomez Maria, Shahraz Saeid, Shepard Donald S, Shin Hwashin, Shivakoti Rupak, Silberberg Donald, Singh David, Singh Gitanjali M, Singh Jasvinder A, Singleton Jessica, Sleet David A, Sliwa Karen, Smith Emma, Smith Jennifer L, Stapelberg Nicolas JC, Steer Andrew, Steiner Timothy, Stolk Wilma A, Stovner Lars Jacob, Sudfeld Christopher, Syed Sana, Tamburlini Giorgio, Tavakkoli Mohammad, Taylor Hugh R, Taylor Jennifer A, Taylor William J, Thomas Bernadette, Thomson W Murray, Thurston George D, Tleyjeh Imad M, Tonelli Marcello, Towbin Jeffrey A, Truelsen Thomas, Tsilimbaris Miltiadis K, Ubeda Clotilde, Undurraga Eduardo A, van der Werf Marieke J, van Os Jim, Vavilala Monica S, Venketasubramanian N, Wang Mengru, Wang Wenzhi, Watt Kerrianne, Weatherall David J, Weinstock Martin A, Weintraub Robert, Weisskopf Marc G, Weissman Myrna M, White Richard A, Whiteford Harvey, Wiebe Natasha, Wiersma Steven T, Wilkinson James D, Williams Hywel C, Williams Sean RM, Witt Emma, Wolfe Frederick, Woolf Anthony D, Wulf Sarah, Yeh Pon-Hsiu, Zaidi Anita KM, Zheng Zhi-Jie, Zonies David, Lopez Alan D, Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010, 10.1016/s0140-6736(12)61689-4
  61. Georgopapadakou Nafsika H, The wobbly status of ketolides: where do we stand?, 10.1517/13543784.2014.954036
  62. Echols Roger M., Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world : Regulatory hurdles for antibacterial drug development, 10.1111/j.1749-6632.2011.06300.x
  63. Fernandes Prabhavathi, Investment in antibiotics against pneumonia, 10.1016/s1473-3099(15)70057-5
  64. Mushtaq Ammara, Solithromycin to treat community-acquired pneumonia?, 10.1016/s2213-2600(15)00188-5
  65. Head Michael G, Fitchett Joseph R, Newell Marie-Louise, Scott J Anthony G, Clarke Stuart C, Atun Rifat, Investment in pneumonia and pneumococcal research, 10.1016/s1473-3099(14)70949-1
  66. Van Bambeke Françoise, Tulkens Paul M., Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin : Comparison with Other Fluoroquinolones and Other Antibacterial Classes, 10.2165/00002018-200932050-00001
Bibliographic reference Van Bambeke, Françoise ; Tulkens, Paul M.. The role of solithromycin in the management of bacterial community-acquired pneumonia.. In: Expert Review of Anti-infective Therapy, Vol. 14, no.3, p. 311-324 (2016)
Permanent URL http://hdl.handle.net/2078.1/174567